These results were remarkably similar to the MONARCH 1 study, where patients with ER+/HER2-breast cancer received abemaciclib following prior ET and chemotherapy but were CDK4/6 inhibitor naïve (Dickler et al., 2017). Here, ESR1 is linked to breast carcinoma.